A new gene expression study is uncovering how colon cancer cells respond to ferroptosis—an iron-dependent form of cell death that is gaining attention as a potential cancer therapy target. The findings point to a shared molecular signature that could help guide future treatment strategies, especially for tumors resistant to conventional approaches.
Published in Frontiers in Molecular Biosciences, the study examined genome-wide gene expression changes in colon cancer cell lines exposed to erastin, a widely used ferroptosis inducer. While individual cell lines showed distinct responses, Sciome and NIEHS researchers identified a core set of 26 genes that were consistently regulated across models.
Several of the most strongly induced genes, including ASNS, CHAC1, PCK2, and DDIT4, are involved in stress response, metabolism, and redox control—suggesting that ferroptosis activates broad adaptive programs as cancer cells attempt to cope with oxidative damage.
The shared gene signature was confirmed in a third colon cancer cell line, reinforcing its robustness. Pathway analyses further highlighted links to oxidative stress defense, amino acid metabolism, and energy regulation.
Ferroptosis has emerged as a mechanistically distinct way to kill cancer cells, driven by iron accumulation and lipid peroxidation. By pinpointing genes that reliably respond to ferroptotic stress, the study lays the groundwork for biomarkers and combination therapies aimed at exploiting this vulnerability in colorectal cancer. Read the publication here.
